Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

[1]  R. Cook,et al.  Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD , 2017, Hepatology.

[2]  W. Kim,et al.  OriginalClinicalScienceçLiver Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States , 2018 .

[3]  J. Sydor,et al.  Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir , 2017, Drug Metabolism and Disposition.

[4]  R. Menon,et al.  Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection , 2017, European Journal of Drug Metabolism and Pharmacokinetics.

[5]  R. Preston,et al.  Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment , 2017, Clinical Pharmacokinetics.

[6]  V. Fischer,et al.  Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans , 2016, Drug Metabolism and Disposition.

[7]  V. Fischer,et al.  Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans , 2016, Drug Metabolism And Disposition.

[8]  J. Sydor,et al.  Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans , 2016, Drug Metabolism and Disposition.

[9]  S. Dutta,et al.  Drug–Drug Interaction of Omeprazole With the HCV Direct‐Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir , 2016, Clinical pharmacology in drug development.

[10]  K. Reddy,et al.  Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. , 2016, Gastroenterology.

[11]  D. Bernstein,et al.  Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. , 2016, Journal of hepatology.

[12]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[13]  M. King,et al.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. , 2015, Journal of hepatology.

[14]  P. Messa,et al.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis , 2015, Digestive Diseases and Sciences.

[15]  S. Dutta,et al.  Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. , 2015, Journal of hepatology.

[16]  K. Kalantar-Zadeh,et al.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans , 2015, Hepatology.

[17]  A. Mathias,et al.  Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir , 2015, Clinical Pharmacokinetics.

[18]  S. Tan,et al.  Hepatitis C and kidney disease: An overview and approach to management. , 2015, World journal of hepatology.

[19]  Shang-Jyh Hwang,et al.  Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis , 2014, PloS one.

[20]  Richard D Moore,et al.  Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. , 2013, The Journal of infectious diseases.

[21]  Yu-Chieh Su,et al.  Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan , 2013, BMC Nephrology.

[22]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[23]  P. Messa,et al.  Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? , 2012, Journal of viral hepatitis.

[24]  L. Fried,et al.  HCV infection and the incidence of CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  E. Vittinghoff,et al.  Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. , 2007, Archives of internal medicine.

[26]  P. Rosenthal,et al.  American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.

[27]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.